DalbergiphenolCAS# 52811-31-1 |
- (+)-Dalbergiphenol
Catalog No.:BCN9262
CAS No.:82358-44-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 52811-31-1 | SDF | Download SDF |
| PubChem ID | 44446855 | Appearance | Powder |
| Formula | C17H18O3 | M.Wt | 270.32 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 2,4-dimethoxy-5-[(1S)-1-phenylprop-2-enyl]phenol | ||
| SMILES | COC1=CC(=C(C=C1C(C=C)C2=CC=CC=C2)O)OC | ||
| Standard InChIKey | SLLCQEPKLKMZKP-ZDUSSCGKSA-N | ||
| Standard InChI | InChI=1S/C17H18O3/c1-4-13(12-8-6-5-7-9-12)14-10-15(18)17(20-3)11-16(14)19-2/h4-11,13,18H,1H2,2-3H3/t13-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Dalbergiphenol treatment can effectively prevent OVX-induced increase in bone loss and decrease in bone strength possibly by increasing osteoblastic activities and by decreasing osteoclastic activities. 2. Dalbergiphenol shows antiosteoporotic activity. |
Dalbergiphenol Dilution Calculator
Dalbergiphenol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.6993 mL | 18.4966 mL | 36.9932 mL | 73.9864 mL | 92.483 mL |
| 5 mM | 0.7399 mL | 3.6993 mL | 7.3986 mL | 14.7973 mL | 18.4966 mL |
| 10 mM | 0.3699 mL | 1.8497 mL | 3.6993 mL | 7.3986 mL | 9.2483 mL |
| 50 mM | 0.074 mL | 0.3699 mL | 0.7399 mL | 1.4797 mL | 1.8497 mL |
| 100 mM | 0.037 mL | 0.185 mL | 0.3699 mL | 0.7399 mL | 0.9248 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- L-Quisqualic acid
Catalog No.:BCC6568
CAS No.:52809-07-1
- Isobavachromene
Catalog No.:BCN3192
CAS No.:52801-22-6
- (±)-Galgravin
Catalog No.:BCN8283
CAS No.:528-63-2
- Cyanidin Chloride
Catalog No.:BCN1231
CAS No.:528-58-5
- Delphinidin chloride
Catalog No.:BCN3015
CAS No.:528-53-0
- Fisetin
Catalog No.:BCN5024
CAS No.:528-48-3
- Magnolol
Catalog No.:BCN5687
CAS No.:528-43-8
- H-Phe(3,4-DiCl)-OH
Catalog No.:BCC3178
CAS No.:52794-99-7
- H-D-Phe(3,4-DiCl)-OH
Catalog No.:BCC3179
CAS No.:52794-98-6
- PHA 568487
Catalog No.:BCC7574
CAS No.:527680-57-5
- Medicarpin 3-O-glucoside
Catalog No.:BCN7773
CAS No.:52766-70-8
- beta-Asarone
Catalog No.:BCN5685
CAS No.:5273-86-9
- Cearoin
Catalog No.:BCN7772
CAS No.:52811-37-7
- Olean-12-ene-3,11-diol
Catalog No.:BCN5686
CAS No.:5282-14-4
- 20-Hydroxyecdysone
Catalog No.:BCN5688
CAS No.:5289-74-7
- Chamazulene
Catalog No.:BCC8145
CAS No.:529-05-5
- Ombuin
Catalog No.:BCN5691
CAS No.:529-40-8
- Myricetin
Catalog No.:BCN5692
CAS No.:529-44-2
- Gentisein
Catalog No.:BCN3356
CAS No.:529-49-7
- Azaleatin
Catalog No.:BCN8207
CAS No.:529-51-1
- Scutellarein
Catalog No.:BCN5380
CAS No.:529-53-3
- Prunin
Catalog No.:BCN5693
CAS No.:529-55-5
- Genistin
Catalog No.:BCN2396
CAS No.:529-59-9
- Euxanthone
Catalog No.:BCN5694
CAS No.:529-61-3
Neoflavonoid dalbergiphenol from heartwood of Dalbergia sissoo acts as bone savior in an estrogen withdrawal model for osteoporosis.[Pubmed:25850356]
Menopause. 2015 Nov;22(11):1246-55.
OBJECTIVE: Dalbergiphenol (DGP) is a neoflavonoid isolated from heartwood of Dalbergia sissoo. Effects of DGP on skeletal health remain to be elucidated. The objective of the present study was to investigate the biological effects of DGP on bone loss in ovariectomized mice. METHODS: Adult BALB/c mice were ovariectomized and administered DGP (1 and 5 mg/kg/d) or 17beta-estradiol (E2) orally for 6 weeks. The sham group and the ovariectomy (OVX) + vehicle group served as controls. Eight female BALB/c mice were taken for each group. Uterine estrogenicity, bone microarchitecture, biomechanical strength, new bone formation (based on bone formation rate and mineral apposition rate), and skeletal expression of osteogenic and resorptive gene markers were studied. RESULTS: OVX resulted in a marked increase in body weight and a decrease in femoral and vertebral trabecular bone volume that were prevented by DGP or E2 treatment. DGP treatment increased bone biomechanical strength and new bone formation rate in ovariectomized mice, comparable with E2 treatment. However, increase in uterine weight and estrogenicity were observed in E2-treated ovariectomized mice, but not in response to DGP treatment. Treatment with DGP increased messenger RNA expression of runt-related transcription factor 2, osterix, and collagen type I, and decreased messenger RNA expression of tartrate-resistant acid phosphatase and the osteoprotegerin-to-receptor activator of nuclear factor-kappaB ligand ratio in the femur of ovariectomized mice. CONCLUSIONS: Overall findings suggest that DGP treatment can effectively prevent OVX-induced increase in bone loss and decrease in bone strength possibly by increasing osteoblastic activities and by decreasing osteoclastic activities.
Neoflavonoids as potential osteogenic agents from Dalbergia sissoo heartwood.[Pubmed:24803361]
Bioorg Med Chem Lett. 2014 Jun 15;24(12):2664-8.
The present study was undertaken to investigate and rationalize the in vitro antiosteoporotic activity of neoflavonoids, isolated from Dalbergia sissoo heartwood. Neoflavonoids were isolated using extensive column chromatography and identified as dalsissooal (1) a new compound and cearoin (2), dalbergin (3), 4-methoxy dalbergion (4), Dalbergiphenol (5), dalbergichromene (6), methyl dalbergin (7) and latinone (8) as known compounds by comparison their spectroscopic data with those reported in the literature. Among the screened compounds, compounds 1, 3, 5-8 significantly increased proliferation as assessed by alkaline phosphatase activity and mineralization in calvarial osteoblast cells.
